Academic Journal
Cohort profile - the Renal cell cancer: Lifestyle, prognosis and quality of life (ReLife) study in the Netherlands.
| Τίτλος: | Cohort profile - the Renal cell cancer: Lifestyle, prognosis and quality of life (ReLife) study in the Netherlands. |
|---|---|
| Συγγραφείς: | Maurits JSF; Department for Health Evidence, Radboud Univerity Medical Center, Nijmegen, The Netherlands., Sedelaar JPM; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Aben KKH; Department for Health Evidence, Radboud Univerity Medical Center, Nijmegen, The Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands., Kampman E; Department for Health Evidence, Radboud Univerity Medical Center, Nijmegen, The Netherlands.; Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands., Kiemeney LALM; Department for Health Evidence, Radboud Univerity Medical Center, Nijmegen, The Netherlands., Vrieling A; Department for Health Evidence, Radboud Univerity Medical Center, Nijmegen, The Netherlands Alina.Vrieling@radboudumc.nl. |
| Συλλογικό Έργο: | ReLife study group |
| Πηγή: | BMJ open [BMJ Open] 2023 Mar 27; Vol. 13 (3), pp. e066909. Date of Electronic Publication: 2023 Mar 27. |
| Τύπος έκδοσης: | Journal Article; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [London] : BMJ Publishing Group Ltd, 2011- |
| Ιατρικοί όροι (MeSH): | Carcinoma, Renal Cell*/epidemiology , Carcinoma, Renal Cell*/therapy , Kidney Neoplasms*/epidemiology , Kidney Neoplasms*/therapy, Netherlands/epidemiology ; Humans ; Male ; Middle Aged ; Aged ; Quality of Life ; Prospective Studies ; Life Style ; Prognosis |
| Περίληψη: | Purpose: The Renal cell cancer: Lifestyle, prognosis and quality of life (ReLife) study is set up to obtain insight into the association of patient and tumour characteristics, lifestyle habits and circulating biomarkers with body composition features in patients with localised renal cell cancer (RCC). Further, it aims to assess the association of body composition features, lifestyle habits and circulating biomarkers with clinical outcomes, including health-related quality of life. Participants: The ReLife study is a multicentre prospective cohort study involving 368 patients with newly diagnosed stages I-III RCC recruited from January 2018 to June 2021 from 18 hospitals in the Netherlands. At 3 months, 1 year and 2 years after treatment, participants fill out a general questionnaire and questionnaires about their lifestyle habits (eg, diet, physical activity, smoking and alcohol consumption), medical history and health-related quality of life. At all three time points, patients wear an accelerometer and have blood samples taken. CT scans for body composition analysis are being collected. Permission is asked for collection of tumour samples. Information about disease characteristics, treatment of the primary tumour and clinical outcomes is being collected from medical records by the Netherlands Cancer Registry. Findings to Date: A total of 836 invited patients were eligible and 368 patients were willing to participate and were included (response rate 44%). The mean age of patients was 62.5±9.0 years and 70% was male. The majority had stage I (65%) disease and were treated with radical nephrectomy (57%). Data collection at 3 months and 1 years after treatment have been finalised. Future Plans: Data collection at 2 years after treatment is expected to be finalised in June 2023 and longitudinal clinical data will continue to be collected. Results of studies based on this cohort are important to develop personalised evidence-based lifestyle advice for patients with localised RCC to enable them to get more control over their disease course. (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Competing Interests: | Competing interests: None declared. |
| References: | J Urol. 2016 Feb;195(2):270-6. (PMID: 26292038) Eur Urol Focus. 2018 Apr;4(3):420-434. (PMID: 28753824) World J Urol. 2010 Jun;28(3):319-27. (PMID: 20364259) J Urol. 2006 Oct;176(4 Pt 1):1631-5. (PMID: 16952705) Eur J Cancer. 2012 Aug;48(12):1822-30. (PMID: 22365640) Eur Urol. 2016 Sep;70(3):458-66. (PMID: 26149669) Br J Nutr. 2011 Jul;106(2):274-81. (PMID: 21338536) Ned Tijdschr Geneeskd. 2014;159:A8085. (PMID: 25515397) Clin Nutr. 2022 Jan;41(1):131-143. (PMID: 34872047) Eur J Cancer. 2016 Apr;57:58-67. (PMID: 26882087) Crit Rev Oncol Hematol. 2020 Jan;145:102839. (PMID: 31877534) Behav Res Methods. 2009 Nov;41(4):1149-60. (PMID: 19897823) Urol Int. 2010;85(1):30-6. (PMID: 20693825) Adv Exp Med Biol. 2017;1043:9-27. (PMID: 29224088) Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006. (PMID: 18923576) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Lancet. 2008 Feb 16;371(9612):569-78. (PMID: 18280327) Jpn J Clin Oncol. 2015 Feb;45(2):210-6. (PMID: 25420691) World J Urol. 2018 Dec;36(12):1953-1959. (PMID: 29767327) J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. (PMID: 8433390) Med Eng Phys. 2007 Oct;29(8):930-4. (PMID: 17134934) Eur Urol. 2022 Oct;82(4):399-410. (PMID: 35346519) J Endourol. 2014 Jul;28(7):861-70. (PMID: 24555480) Eur J Clin Nutr. 2009 Feb;63 Suppl 1:S69-74. (PMID: 19190649) Eur Urol. 2008 Oct;54(4):866-73. (PMID: 18343565) J Endourol. 2015 Mar;29(3):372-6. (PMID: 25203393) Nat Rev Urol. 2010 May;7(5):245-57. (PMID: 20448658) BMC Cancer. 2012 Sep 08;12:399. (PMID: 22958305) J Appl Physiol (1985). 2004 Dec;97(6):2333-8. (PMID: 15310748) Int J Cancer. 2013 Feb 1;132(3):625-34. (PMID: 22610826) Am J Clin Nutr. 2004 Aug;80(2):271-8. (PMID: 15277145) Eur Urol. 2019 Jan;75(1):74-84. (PMID: 30243799) J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):636-649. (PMID: 32125769) Int J Urol. 2015 May;22(5):455-61. (PMID: 25631365) Jpn J Clin Oncol. 2008 Feb;38(2):106-11. (PMID: 18245516) J Clin Epidemiol. 2003 Dec;56(12):1163-9. (PMID: 14680666) Eur J Cancer Care (Engl). 2018 Mar;27(2):e12611. (PMID: 27921375) J Urol. 2021 Feb;205(2):346-355. (PMID: 32945696) Maturitas. 2010 Apr;65(4):315-9. (PMID: 20079586) Adipocyte. 2021 Dec;10(1):285-292. (PMID: 34014795) Urol Oncol. 2019 Jun;37(6):359-371. (PMID: 30685335) Nutr J. 2013 Jun 07;12:75. (PMID: 23758629) Eur Urol Focus. 2016 Jun;2(2):197-203. (PMID: 28723535) Br J Cancer. 2011 Dec 6;105 Suppl 2:S34-7. (PMID: 22158318) |
| Contributed Indexing: | Investigator: D van derSchoot; A Niemer; DM Somford; WA Scheepens; P Kil; BP Wijsman; PJ van Hest; DM Bochove-Overgaauw; S van derMeer; E van Boven; L Fossion; K de Laet; FS van Rey; G Smits; A Geboers; WJ Kniestedt; RP Meijer; M Kortleve; S Stomps Keywords: Epidemiology; Kidney tumours; NUTRITION & DIETETICS; PREVENTIVE MEDICINE |
| Entry Date(s): | Date Created: 20230327 Date Completed: 20230329 Latest Revision: 20230407 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10069500 |
| DOI: | 10.1136/bmjopen-2022-066909 |
| PMID: | 36972960 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2044-6055 |
|---|---|
| DOI: | 10.1136/bmjopen-2022-066909 |